A rapidly progressing Pancoast syndrome due to pulmonary mucormycosis: a case report
© Bansal et al; licensee BioMed Central Ltd. 2011
Received: 18 April 2011
Accepted: 17 August 2011
Published: 17 August 2011
Pancoast syndrome is characterized by Horner syndrome, shoulder pain radiating down the arm, compression of the brachial blood vessels, and, in long-standing cases, atrophy of the arm and hand muscles. It is most commonly associated with lung carcinoma but rarely is seen with certain infections.
We present the case of a 51-year-old Caucasian man who had acute myeloid leukemia and who developed a rapidly fulminating pneumonia along with signs and symptoms of acute brachial plexopathy and left Horner syndrome. Also, a purpuric plaque developed over his left chest wall and progressed to skin necrosis. The skin biopsy and bronchoalveolar lavage showed a Rhizopus species, leading to a diagnosis of mucormycosis. This is a rare case of pneumonia due to mucormycosis associated with acute Pancoast syndrome.
According to our review of the literature, only a few infectious agents have been reported to be associated with Pancoast syndrome. We found only three case reports of mucormycosis associated with acute Pancoast syndrome. Clinicians should consider mucormycosis in their differential diagnosis in a patient with pulmonary lesions and chest wall invasion with or without neurological symptoms, especially in the setting of neutropenia or other immunosuppressed conditions. It is important to recognize this condition early in order to target therapy and interventions.
Pancoast syndrome is most commonly associated with a primary lung carcinoma and rarely with metastatic malignancies and certain infections, including mucormycosis. It is characterized by Horner syndrome, shoulder pain radiating down the arm, compression of the brachial blood vessels, and, in long-standing cases, atrophy of the arm and hand muscles. Pulmonary mucormycosis usually occurs in the setting of hematological malignancies. The typical presentation is a patient with neutropenic fever, pulmonary infiltrates, and a clinical course that worsens despite antibiotics. We present a case of pulmonary mucormycosis associated with postchemotherapy neutropenia in a patient with acute myeloid leukemia. His course was fulminating, leading to chest wall invasion, brachial plexopathy, and Horner syndrome.
A 51-year-old Caucasian man was hospitalized for the management of a relapse of acute myeloid leukemia. He had hyperleukocytosis and complained of mild shortness of breath and generalized weakness. He denied cough, fevers or chills, hemoptysis, or orthopnea. He had smoked 39 pack years. His significant medical history began six months prior to admission, when his condition was diagnosed as acute myelomonocytic leukemia. He had been treated with cytarabine and daunorubicin followed by high-dose cytarabine. Shortly after admission, he required urgent leukopheresis because of worsening hyperleukocytosis and acute respiratory failure. He recovered and had further chemotherapy with clofarabine and cytarabine.
Mucormycosis is an uncommon opportunistic infection, but its incidence is increasing as the number of patients with diabetes, organ transplants, or immunosuppressed conditions continues to rise . Hematological malignancies are more frequently associated with mucormycosis than solid tumors are . In patients with hematological malignancies, mucormycosis affects the lungs most frequently (58% to 81%) .
Pulmonary mucormycosis occurs with inhalation of spores into the bronchioles and alveoli, usually resulting in a rapidly progressive pneumonia or endobronchial disease. Symptoms are typically nonspecific and may include fever, dyspnea, cough, and chest pain [2, 3]. The infection can spread to contiguous organs or disseminate hematogenously. Of particular interest to our case is the overwhelming speed with which the process extended from the lung parenchyma to the surrounding structures (tissue, nerves, vessels, and skin). The progression of symptoms suggests that the lower brachial plexus trunk became ischemic initially and that the rest of the plexus followed as the lesion extended from the lung to the surrounding tissues. Mucor is known to locally invade nerves, most often in rhinocerebral disease. Common clinical findings include rhinitis, periorbital and facial swelling, mucosal necrosis, ophthalmoplegia, multiple cranial nerve palsies, facial pain, and headache . Whereas stroke from rhinocerebral mucormycosis causing occlusion of the cavernous portion of the internal carotid is well documented , involvement of the brachial vascular and nervous plexus is a very unusual presentation. Three reports document mucormycosis presenting as a Pancoast syndrome [5–7]. Notably, two had diabetes (both survived) as their only risk factor and one had acute lymphoblastic leukemia (died).
Pancoast syndrome is characterized by Horner syndrome (ptosis, miosis, hemianhidrosis, and enophthalmos), shoulder pain radiating toward the axilla or ulnar aspect of the arm, compression of the brachial blood vessels, and atrophy of the arm and hand muscles. This syndrome is most commonly caused by a bronchogenic carcinoma in the superior sulcus of the lung with destructive lesions of the thoracic inlet and invasion of the brachial plexus and cervicothoracic sympathetic chain. Other causes include metastatic neoplasms and infections. In a recent review of 31 patients with infectious causes of Pancoast syndrome, five were immunocompromised (acute myelogenous leukemia, acute lymphoblastic leukemia, and postchemotherapy), and all had opportunistic organisms (Aspergillus spp., mucor, nocardia, and Pseudoallescheria boydii) . In contrast, only one of the 26 immunocompetent patients had an opportunistic organism.
In immunocompromised patients, it can be challenging to distinguish pulmonary disease caused by mucormycosis from that caused by aspergillosis. The concomitant presence of sinusitis or a history of voriconazole prophylaxis may suggest mucormycosis [8, 9]. Of note, our patient received voriconazole prophylaxis. The radiographic presentation of pulmonary mucormycosis can be diverse, and there are no pathognomonic radiographic features. In a review of imaging findings in 32 cases of mucormycosis, two thirds of the patients had consolidation as a main finding . Other radiographic manifestations include cavitation, mass-like lesions, widened mediastinum, an "air crescent sign", "halo sign", pleural effusion, and fistula to the chest wall [10, 11]. Chamilos and colleagues , in a retrospective chart review, found that multiple nodules (at least 10) and the presence of pleural effusion were more often found in mucormycosis than in aspergillosis.
Definitive diagnosis of mucormycosis often evades initial noninvasive techniques such as sputum and blood cultures. The organism may be recovered by bronchoscopy with bronchoalveolar lavage or transbronchial lung biopsy. However, because of the focal distribution of the disease, transthoracic computed tomography-guided needle biopsy or open lung biopsy may be required to make the diagnosis in pulmonary disease [1, 12, 13]. Histology is characterized by infarction and necrosis of tissue which results from an invasion of the vasculature by hyphae. The fungus can also be associated with neural, vascular, and cutaneous invasion, as in our patient. The fungus is usually recognized by broad, irregular, nonseptate, right-angled, branching hyphae and is demonstrated by hematoxylin and eosin and specialized fungal stains. In contrast, Aspergillus hyphae are narrow with septate branches at 45° angles. As with other fungal diseases, mucorales rarely grow by culture.
Treatment of mucormycosis involves a combination of surgical debridement of involved tissues and antifungal therapy with varying degrees of success, as noted in the literature [1, 14, 15]. Amphotericin B is the first-line antifungal treatment; delays in instituting therapy may be associated with increased mortality. Elimination of predisposing factors for infection, such as hyperglycemia, metabolic acidosis, and neutropenia, is critical. Pulmonary mucormycosis carries a very high mortality rate (60% to 90%) [1, 14].
It is important to consider the diagnosis of mucormycosis in a patient with pulmonary lesions and chest wall invasion with or without neurological symptoms, especially in the setting of neutropenia or other immunosuppressed conditions. Our patient had a rapid progression to multiorgan failure and refractory shock despite being treated with amphotericin B and died within two days of his diagnosis.
Written informed consent was obtained from the next of kin for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Lee FY, Mossad SB, Adal KA: Pulmonary mucormycosis: the last 30 years. Arch Intern Med. 1999, 159: 1301-1309. 10.1001/archinte.159.12.1301.View ArticlePubMedGoogle Scholar
- Pagano L, Offidani M, Fianchi L, Nosari A, Candoni A, Piccardi M, Corvatta L, D'Antonio D, Girmenia C, Martino P, Del Favero A: Mucormycosis in hematologic patients. Haematologica. 2004, 89: 207-214.PubMedGoogle Scholar
- Bigby TD, Serota ML, Tierney LM, Matthay MA: Clinical spectrum of pulmonary mucormycosis. Chest. 1986, 89: 435-439. 10.1378/chest.89.3.435.View ArticlePubMedGoogle Scholar
- Warwar RE, Bullock JD: Rhino-orbital-cerebral mucormycosis: a review. Orbit. 1998, 17: 237-245. 10.1076/orbi.184.108.40.20642.View ArticlePubMedGoogle Scholar
- Kotoulas C, Psathakis K, Tsintiris K, Sampaziotis D, Karnesis L, Laoutidis G: Pulmonary mucormycosis presenting as horner's syndrome. Asian Cardiovasc Thorac Ann. 2006, 14: 86-87.View ArticlePubMedGoogle Scholar
- Levy H, Sacho H, Feldman C, Naude GE, Peskin J, Stead KJ, Kallenbach JM: Pulmonary mucormycosis presenting with horner's syndrome. Report of a medical cure. S Afr Med J. 1986, 70: 363-365.PubMedGoogle Scholar
- White HD, White BA, Boethel C, Arroliga AC: Pancoast's syndrome secondary to infectious etiologies: a not so uncommon occurrence. Am J Med Sci. 2011, 341: 333-336. 10.1097/MAJ.0b013e3181fa2e2d.View ArticlePubMedGoogle Scholar
- Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP: Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis. 2005, 41: 60-66. 10.1086/430710.View ArticlePubMedGoogle Scholar
- Trifilio S, Singhal S, Williams S, Frankfurt O, Gordon L, Evens A, Winter J, Tallman M, Pi J, Mehta J: Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant. 2007, 40: 451-456. 10.1038/sj.bmt.1705754.View ArticlePubMedGoogle Scholar
- McAdams HP, Rosado de Christenson M, Strollo DC, Patz EF: Pulmonary mucormycosis: radiologic findings in 32 cases. AJR Am J Roentgenol. 1997, 168: 1541-1548.View ArticlePubMedGoogle Scholar
- Murphy RA, Miller WT: Pulmonary mucormycosis. Semin Roentgenol. 1996, 31: 83-87. 10.1016/S0037-198X(96)80043-5.View ArticlePubMedGoogle Scholar
- Kim K, Lee MH, Kim J, Lee KS, Kim SM, Jung MP, Han J, Sung KW, Kim WS, Jung CW, Yoon SS, Im YH, Kang WK, Park K, Park CH: Importance of open lung biopsy in the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies. Am J Hematol. 2002, 71: 75-79. 10.1002/ajh.10168.View ArticlePubMedGoogle Scholar
- Eucker J, Sezer O, Graf B, Possinger K: Mucormycoses. Mycoses. 2001, 44: 253-260. 10.1111/j.1439-0507.2001.00656.x.View ArticlePubMedGoogle Scholar
- Tedder M, Spratt JA, Anstadt MP, Hegde SS, Tedder SD, Lowe JE: Pulmonary mucormycosis: results of medical and surgical therapy. Ann Thorac Surg. 1994, 57: 1044-1050. 10.1016/0003-4975(94)90243-7.View ArticlePubMedGoogle Scholar
- Gleissner B, Schilling A, Anagnostopolous I, Siehl I, Thiel E: Improved outcome of zygomycosis in patients with hematological diseases?. Leuk Lymphoma. 2004, 45: 1351-1360. 10.1080/10428190310001653691.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.